

North America Dengue Treatment Market

Market Report | 2024-06-01 | 194 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America dengue treatment market is expected to reach USD 311.62 million by 2031, from USD 143.29 million in 2023, growing at the CAGR of 10.2% in the forecast period of 2024 to 2031.

Market Segmentation:

North America Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

Overview of North America Dengue Treatment Market Dynamics:

Driver

- Rising dengue incidence rate result in the demand for effective treatment

Restrain

- Delay in the approval process of vaccines

Opportunity

- Growing number of pipeline vaccines for dengue treatment

Market Players:

The key market players operating in the North America dengue treatment market are listed below:

- Sanofi
- Takeda Pharmaceutical Company Limited

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Perrigo Company PLC
- Baxter
- Fresenius Kabi USA
- Pfizer
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma

Table of Contents:

1 INTRODUCTION	40
1.1 OBJECTIVES OF THE STUDY	40
1.2 MARKET DEFINITION	40
1.3 OVERVIEW OF THE NORTH AMERICA DENGUE TREATMENT MARKET	40
1.4 CURRENCY AND PRICING	42
1.5 LIMITATIONS	42
1.6 MARKETS COVERED	43
2 MARKET SEGMENTATION	46
2.1 MARKETS COVERED	46
2.2 GEOGRAPHICAL SCOPE	47
2.3 YEARS CONSIDERED FOR THE STUDY	48
2.4 DBMR TRIPOD DATA VALIDATION MODEL	49
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	52
2.6 MULTIVARIATE MODELLING	53
2.7 MARKET APPLICATION COVERAGE GRID	54
2.8 PRODUCT LIFELINE CURVE	55
2.9 DBMR MARKET POSITION GRID	56
2.10 VENDOR SHARE ANALYSIS	57
2.11 SECONDARY SOURCES	58
2.12 ASSUMPTIONS	58
3 EXECUTIVE SUMMARY	59
4 PREMIUM INSIGHTS	62
4.1 PESTEL ANALYSIS	63
4.2 PORTER'S FIVE FORCES	64
5 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS	65
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT	66
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT	66
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK	67
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE	67
5.5 DVCN DEVELOPING VACCINE REGULATORS NETWORK	68
6 MARKET OVERVIEW	69
6.1 DRIVERS	71
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT	71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.1.2	RISING WAVE OF DENGUE VACCINE LAUNCHES	71
6.1.3	GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS	72
6.1.4	GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES	73
6.2	RESTRAINTS	74
6.2.1	DELAY IN THE APPROVAL PROCESS OF VACCINES	74
6.2.2	LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE	75
6.2.3	DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE	76
6.3	OPPORTUNITIES	77
6.3.1	STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET	77
6.3.2	GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT	77
6.3.3	RISING R&D INVESTMENT AND ACTIVITIES	78
6.4	CHALLENGES	79
6.4.1	HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS	79
6.4.2	HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS	79
7	NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS	81
7.1	OVERVIEW	82
7.2	DENV-2	85
7.3	DENV-3	85
7.4	DENV-1	86
7.5	DENV-4	86
7.6	OTHERS	87
8	NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE	88
8.1	OVERVIEW	89
8.2	VACCINES	92
8.2.1	DENGVAXIA (CYD-TDV)	93
8.2.2	QDenga	93
8.3	ACETAMINOPHEN	93
8.3.1	PARENTERAL	94
8.3.2	ORAL	94
8.3.3	OTHER	94
9	NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY	95
9.1	OVERVIEW	96
9.2	MILD TO MODERATE DENGUE	99
9.3	SEVERE DENGUE	99
?		
10	NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION	100
10.1	OVERVIEW	101
10.2	PARENTERAL	104
10.2.1	SUB-CUTANEOUS	104
10.2.2	INTRAVENOUS	104
10.3	ORAL	105
10.3.1	TABLET	105
10.3.2	CAPSULES	105
10.3.3	OTHERS	105
11	NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE	106
11.1	OVERVIEW	107
11.2	PRESCRIPTION	110

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3 OVER-THE-COUNTER (OTC)	110
12 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER	111
12.1 OVERVIEW	112
12.2 MALE	115
12.3 FEMALE	115
13 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE	116
13.1 OVERVIEW	117
13.2 ADULT	120
13.3 PEDIATRIC	120
13.4 GERIATRIC	121
14 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER	122
14.1 OVERVIEW	123
14.2 HOSPITAL	126
14.3 SPECIALTY CLINICS	126
14.4 HOME HEALTHCARE	127
14.5 OTHERS	127
15 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL	128
15.1 OVERVIEW	129
15.2 RETAIL PHARMACIES	132
15.3 HOSPITAL PHARMACIES	132
15.4 ONLINE PHARMACIES	133
?	
16 NORTH AMERICA DENGUE TREATMENT MARKET, BY REGION	134
16.1 NORTH AMERICA	137
16.1.1 MEXICO	142
16.1.2 U.S.	147
16.1.3 CANADA	152
17 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE	157
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA	158
17.3 COMPANY SHARE ANALYSIS: EUROPE	159
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC	160
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA	161
18 SWOT ANALYSIS	162
19 COMPANY PROFILE	163
19.1 SANOFI	163
19.1.1 COMPANY SNAPSHOT	163
19.1.2 REVENUE ANALYSIS	163
19.1.3 COMPANY SHARE ANALYSIS	164
19.1.4 PRODUCT PORTFOLIO	164
19.1.5 RECENT DEVELOPMENTS	164
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED	165
19.2.1 COMPANY SNAPSHOT	165
19.2.2 REVENUE ANALYSIS	165
19.2.3 COMPANY SHARE ANALYSIS	166
19.2.4 PRODUCT PORTFOLIO	166
19.2.5 RECENT DEVELOPMENTS	166

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.3 VIATRIS INC.	168
19.3.1 COMPANY SNAPSHOT	168
19.3.2 REVENUE ANALYSIS	169
19.3.3 COMPANY SHARE ANALYSIS	169
19.3.4 PRODUCT PORTFOLIO	169
19.3.5 RECENT DEVELOPMENTS	170
19.4 JOHNSON & JOHNSON SERVICES, INC.	171
19.4.1 COMPANY SNAPSHOT	171
19.4.2 REVENUE ANALYSIS	171
19.4.3 COMPANY SHARE ANALYSIS	172
19.4.4 PRODUCT PORTFOLIO	172
19.4.5 RECENT DEVELOPMENT	172
?	
19.5 GSK PLC.	174
19.5.1 COMPANY SNAPSHOT	174
19.5.2 REVENUE ANALYSIS	174
19.5.3 COMPANY SHARE ANALYSIS	175
19.5.4 PRODUCT PORTFOLIO	175
19.5.5 RECENT DEVELOPMENTS	175
19.6 AUROBINDO PHARMA	176
19.6.1 COMPANY SNAPSHOT	176
19.6.2 REVENUE ANALYSIS	176
19.6.3 PRODUCT PORTFOLIO	177
19.7 BAXTER	178
19.7.1 COMPANY SNAPSHOT	178
19.7.2 REVENUE ANALYSIS	178
19.7.3 PRODUCT PORTFOLIO	179
19.8 FRESENIUS KABI USA	180
19.8.1 COMPANY SNAPSHOT	180
19.8.2 PRODUCT PORTFOLIO	180
19.8.3 RECENT DEVELOPMENTS	180
19.9 HIKMA PHARMACEUTICALS	181
19.9.1 COMPANY SNAPSHOT	181
19.9.2 REVENUE ANALYSIS	181
19.9.3 PRODUCT PORTFOLIO	182
19.9.4 RECENT DEVELOPMENT	182
19.10 PERRIGO COMPANY PLC	183
19.10.1 COMPANY SNAPSHOT	183
19.10.2 REVENUE ANALYSIS	183
19.10.3 PRODUCT PORTFOLIO	184
19.10.4 RECENT DEVELOPMENT	184
19.11 PFIZER INC.	185
19.11.1 COMPANY SNAPSHOT	185
19.11.2 REVENUE ANALYSIS	185
19.11.3 PRODUCT PORTFOLIO	186
19.11.4 RECENT DEVELOPMENTS	186
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD	187

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.12.1	COMPANY SNAPSHOT	187
19.12.2	REVENUE ANALYSIS	188
19.12.3	PRODUCT PORTFOLIO	188
19.12.4	RECENT DEVELOPMENT	188
?		
19.13	TEVA PHARMACEUTICALS USA, INC.	189
19.13.1	COMPANY SNAPSHOT	189
19.13.2	REVENUE ANALYSIS	189
19.13.3	PRODUCT PORTFOLIO	190
19.13.4	RECENT DEVELOPMENT	190
20	QUESTIONNAIRE	191
21	RELATED REPORTS	194

North America Dengue Treatment Market

Market Report | 2024-06-01 | 194 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com